Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
11.37
+0.23 (2.06%)
May 8, 2026, 4:00 PM EDT - Market closed
Immatics Employees
As of December 31, 2025, Immatics had 711 total employees, including 589 full-time and 122 part-time employees. The number of employees increased by 29 or 4.25% compared to the previous year.
Employees
711
Change
29
Growth
4.25%
Revenue / Employee
$79,705
Profits / Employee
-$324,406
Market Cap
1.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 711 | 29 | 4.25% | 589 | 122 |
| Sep 30, 2025 | 645 | 73 | 12.76% | 645 | 0 |
| Mar 31, 2025 | 646 | 111 | 20.75% | 646 | 0 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Sep 30, 2024 | 572 | 139 | 32.10% | 572 | 0 |
| Jun 30, 2024 | 542 | 140 | 34.83% | 542 | 0 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Sep 30, 2023 | 433 | 45 | 11.60% | 433 | 0 |
| Mar 31, 2023 | 402 | 29 | 7.77% | 402 | 0 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Jun 30, 2022 | 388 | 57 | 17.22% | 388 | 0 |
| Mar 31, 2022 | 373 | 90 | 31.80% | 373 | 0 |
| Dec 31, 2021 | 381 | 98 | 34.63% | 314 | 67 |
| Sep 30, 2021 | 331 | 101 | 43.91% | 331 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Iovance Biotherapeutics | 975 |
| Novavax | 749 |
| AbCellera Biologics | 562 |
| Vir Biotechnology | 367 |
| Biohaven | 274 |
| uniQure | 221 |
| Precigen | 160 |
IMTX News
- 11 days ago - Immatics initiated with a Buy at TD Cowen - TheFly
- 17 days ago - Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting - GlobeNewsWire
- 21 days ago - Immatics abstract accepted for late-breaking poster presentation at AACR meeting - TheFly
- 7 weeks ago - Immatics assumed with a Buy at Jefferies - TheFly
- 2 months ago - Immatics sees cash runway into 2028 - TheFly
- 2 months ago - Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year - TheFly
- 2 months ago - Immatics price target raised to $25 from $23 at Mizuho - TheFly
- 3 months ago - Immatics’ treatment of Stage II and higher CM granted FDA orphan designation - TheFly